Skip to main content
Premium Trial:

Request an Annual Quote

ERS Genomics Licenses CRISPR Patents to Nuvisan

NEW YORK – Dublin-based ERS Genomics said on Monday that it has signed a non-exclusive agreement with Nuvisan allowing the firm access to ERS' CRISPR-Cas9 patent portfolio.

Nuvisan, based in Waltrop, Germany, said it will use ERS' portfolio to help advance its clients' drug discovery and early development programs.

A spinout of Bayer, Nuvisan offers integrated programs from target discovery to the clinic, including lead discovery, medicinal chemistry, pharmacology, drug metabolism, and investigational toxicology.

"[CRISPR-Cas9] is revolutionizing drug development, and we are very pleased to now be able add this capability to our service portfolio," Hans Lindner, managing director of Nuvisan, said in a statement.

Financial details of the agreement were not disclosed.

"We are pleased to provide Nuvisan … access to this Nobel Prize winning technology, further expanding the reach of the important gene editing tool and enhancing Nuvisan's portfolio of service offering to organizations in the field of drug development," Erich Rhodes, CEO of ERS Genomics, said in a statement.

ERS has signed multiple licensing deals for its CRISPR-Cas9 patent portfolio, including its most recent agreement with Japan-based Setsuro Tech last month.    

The Scan

University of Michigan President Fired

Mark Schlissel, the president of the University of Michigan, has been fired after an investigation into allegations he had an affair with a subordinate, the Washington Post reports.

Recommendation to Drop Charges

The Wall Street Journal says federal prosecutors recommended charges against MIT's Gang Chen, who was caught up by the China Initiative, be dropped.

Mix 'Em Together

The Guardian reports Moderna is planning to have a combination SARS-CoV-2, influenza, and RSV vaccine by the 2023 flu season.

PNAS Papers on Earth BioGenome Project, SETX Knockouts, Pig Model of Cystic Fibrosis

In PNAS this week: Earth BioGenome Project reports progress, analysis of cells missing the progressive neurodegenerative disease-linked SETX gene, and more.